AbbVie has a strong presence in immunology, oncology and neuroscience areas. Other than that, AbbVie also has products for ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

Pfizer is launching seven phase 3 studies for PF-4044 soon and plans to initiate an additional 10 (at least) by the end of ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...

PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S.

And one of them is pharmaceutical giant Pfizer (NYSE: PFE). Now, with a major step along the path to entering this ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent ...

Pfizer and Astellas Pharma have received FDA approval for PADCEV, an antibody-drug conjugate, in combination with Keytruda as ...

SAN FRANCISCO - Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced Monday the appointment of Roger Dansey, M.D., to its board of directors. The clinical-stage biopharmaceutical company, currently ...

Most of the dividend increases announced in the last two weeks of November were in the low-to-mid single-digit percentages.

Dear reader, oncology medications occupy a prominent position in the global pharmaceutical industry, representing one of the ...

Pfizer & Astellas announce US FDA approves Padcev plus Keytruda for certain patients with bladder cancer: New York Monday, November 24, 2025, 12:00 Hrs [IST] Pfizer Inc. and Astel ...